Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement to the New Drug Application (NDA) for iDose® TR, allowing for the re-administration of the product using a repeat treatment protocol. This approval is based on clinical evidence supporting the safety and tolerability of repeat use of iDose TR. Under the updated labeling, physicians can now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters. Clinical studies and trials have shown that repeated administration of iDose TR is safe and well-tolerated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128062505) on January 28, 2026, and is solely responsible for the information contained therein.